Citations (59)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Jashin J. Wu, Manish Patel, Feng Zeng, Ahong Huang, Xing Pan, Yiwen Cao, Naijun Chen, Huzefa Photowala, Vishvas Garg & Jeff Crowley. (2023) Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States. Journal of Dermatological Treatment 34:1.
Read now
Read now
Lluís Rusiñol, Elena Carmona-Rocha & Lluís Puig. (2023) Durability and long-term outcomes of biologic therapies in psoriasis. Expert Review of Clinical Immunology 0:0, pages 1-12.
Read now
Read now
Helena Iznardo & Lluís Puig. (2020) The safety of brodalumab for the treatment of psoriasis. Expert Opinion on Drug Safety 19:4, pages 365-372.
Read now
Read now
Shany Sherman, Emmilia Hodak & Lev Pavlovsky. (2018) Can etanercept treatment failure in moderate-to-severe psoriasis be overcome by addition of low-dose methotrexate? A single-center experience. Journal of Dermatological Treatment 29:7, pages 666-670.
Read now
Read now
Daniel J. No, Megan S. Inkeles, Mina Amin & Jashin J. Wu. (2018) Drug survival of biologic treatments in psoriasis: a systematic review. Journal of Dermatological Treatment 29:5, pages 460-466.
Read now
Read now
Benjamin Farahnik, Viraat Patel, Kourosh Beroukhim, Tian Hao Zhu, Michael Abrouk, Mio Nakamura, Rasnik Singh, Kristina Lee, Tina Bhutani & John Koo. (2016) Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability. Psoriasis: Targets and Therapy 6, pages 105-111.
Read now
Read now
Melissa B. Hoffman, Dane Hill & Steven R. Feldman. (2016) Current challenges and emerging drug delivery strategies for the treatment of psoriasis. Expert Opinion on Drug Delivery 13:10, pages 1461-1473.
Read now
Read now
T. Torres, M. Romanelli & A. Chiricozzi. (2016) A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opinion on Investigational Drugs 25:7, pages 751-754.
Read now
Read now
Michel de la Brassinne, Pierre-Dominique Ghislain, Jo L. W. Lambert, Julien Lambert, Siegfried Segaert & Fabienne Willaert. (2016) Recommendations for managing a suboptimal response to biologics for moderate-to-severe psoriasis: A Belgian perspective. Journal of Dermatological Treatment 27:2, pages 128-133.
Read now
Read now
Ian TY Wong, Kam Shojania, Jan Dutz & Nicole W Tsao. (2016) Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis. Expert Review of Pharmacoeconomics & Outcomes Research 16:2, pages 153-166.
Read now
Read now
Alessia Alunno, Francesco Carubbi, Giacomo Cafaro, Giacomo Pucci, Francesca Battista, Elena Bartoloni, Roberto Giacomelli, Giuseppe Schillaci & Roberto Gerli. (2015) Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis. Expert Opinion on Biological Therapy 15:12, pages 1727-1737.
Read now
Read now
Jo Lambert, Alexander Nast, Frank O. Nestle & Jörg C Prinz. (2015) Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases?. Journal of Dermatological Treatment 26:6, pages 520-527.
Read now
Read now
Articles from other publishers (47)
Shadi Askari, Alireza Ghofrani & Hamed Taherdoost. (2023) Transforming Drug Design: Innovations in Computer-Aided Discovery for Biosimilar Agents. BioMedInformatics 3:4, pages 1178-1196.
Crossref
Crossref
Kim A. Papp, Andrew Blauvelt, Lluís Puig, Mamitaro Ohtsuki, Stefan Beissert, Melinda Gooderham, Ahmad Z. Amin, Jie Liu, Tianshuang Wu, Tofial Azam, Vassilis Stakias, Ramon Espaillat, Ranjeeta Sinvhal, Ahmed M. Soliman, Yinuo Pang, Michael M. Chen & Mark G. Lebwohl. (2023) Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up. Journal of the American Academy of Dermatology 89:6, pages 1149-1158.
Crossref
Crossref
Harshavardhan Bhuktar, Sharda Shukla, Kumar Reddy Kakularam, Srikanth Battu, Manupati Srikanth, Susmita Srivastava, Raghavender Medishetti, Pooja Ram, P.C. Jagadish, Mahaboobkhan Rasool, Sandipan Chakraborty, Nooruddin Khan, Pallu Reddanna, Srinivas Oruganti & Manojit Pal. (2023) Design, synthesis and evaluation of 2-aryl quinoline derivatives against 12R-lipoxygenase (12R-LOX): Discovery of first inhibitor of 12R-LOX. Bioorganic Chemistry 138, pages 106606.
Crossref
Crossref
Tae-Hwan Kim, Mitsumasa Kishimoto, James Cheng-Chung Wei, Haeyoun Jeong, Akiyo Nozaki & Shigeto Kobayashi. (2023) Brodalumab, an anti–interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study. Rheumatology 62:5, pages 1851-1859.
Crossref
Crossref
Mette Reilev, Peter Bjødstrup Jensen, Lise Skov Ranch, Alexander Egeberg, Kari Furu, Karin Gembert, David Hagg, Ulrike Haug, Øystein Karlstad, Johan Reutfors, Wiebke Schäfer, Sarina Schwartz, Elisabeth Smits, Emily Holthius, Ron Herings, Gianluca Trifirò, Ursula Kirchmayer, Alessandro Cesare Rosa, Valeria Belleudi, Rosa Gini, Henrik Støvring & Jesper Hallas. (2023) Methodology of the brodalumab assessment of hazards: a multicentre observational safety (BRAHMS) study. BMJ Open 13:2, pages e066057.
Crossref
Crossref
Edward Hadeler, Sugandh Kumar, Samuel Yeroushalmi, Julie Hong, Elizabeth Wallace, George Han, Megan Mosca, Erin Bartholomew, Mimi Chung, Marwa Hakimi, Soumya Reddy, Jose Scher, Tina Bhutani, George Gondo, April Armstrong, Stacie Bell & Wilson Liao. (2022) Factors Associated with Multi-Biologic Use in Psoriasis Patients at an Academic Medical Center and Review of Biologic Survival. Journal of Psoriasis and Psoriatic Arthritis 8:1, pages 11-18.
Crossref
Crossref
Paolo Gisondi, Alice B. Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, José M. López Pinto, Nicola Tilt & Mark Lebwohl. (2022) Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2). Dermatology and Therapy 13:1, pages 315-328.
Crossref
Crossref
Iulia-Alexandra Paliu, Simona-Laura Ianosi, Adina Turcu-Stiolica, Catalina-Gabriela Pisoschi, Luminita-Georgeta Predoi & Andrei-Adrian Tica. (2022) Vitamin D May Be Connected with Health-Related Quality of Life in Psoriasis Patients Treated with Biologics. Journal of Personalized Medicine 12:11, pages 1857.
Crossref
Crossref
K. Reich, L. Iversen, L. Puig, J. Lambert, U. Mrowietz, K. Kaplan Saday & R.B. Warren. (2022) Long‐term efficacy and safety of brodalumab in moderate‐to‐severe plaque psoriasis: a post hoc pooled analysis of AMAGINE‐2 and ‐3. Journal of the European Academy of Dermatology and Venereology 36:8, pages 1275-1283.
Crossref
Crossref
Alexander Egeberg, Nana Aviaaja Lippert Rosenø, David Thein, Erik Hillo Lørup, Mia-Louise Nielsen, Lea Nymand, Lars Erik Kristensen, Jacob P. Thyssen, Simon Francis Thomsen, Rene Lindholm Cordtz, Nikolai Loft, Lone Skov, Lars Erik Bryld, Mads Kirchheiner Rasmussen, Pil Højgaard, Salome Kristensen & Lene Dreyer. (2022) Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries. Seminars in Arthritis and Rheumatism 53, pages 151979.
Crossref
Crossref
R. B. Warren, M. Lebwohl, H. Sofen, V. Piguet, M. Augustin, F. Brock, C. Arendt, F. Fierens & A. Blauvelt. (2021) Three‐year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. Journal of the European Academy of Dermatology and Venereology 35:12, pages 2398-2408.
Crossref
Crossref
Marcus Schmitt-Egenolf, Jonatan Freilich, Natalia M. Stelmaszuk-Zadykowicz, Eydna Apol, Jes B. Hansen & Lars-Åke Levin. (2021) Drug Persistence of Biologic Treatments in Psoriasis: A Swedish National Population Study. Dermatology and Therapy 11:6, pages 2107-2121.
Crossref
Crossref
Antonio Costanzo, Filomena Russo, Marco Galluzzo, Luca Stingeni, Roberta Scuderi, Leonardo Zichichi, Manuela Papini, Luisa Di Costanzo, Andrea Conti, Martina Burlando, Andrea Chiricozzi, Francesca Maria Gaiani, Cristina Mugheddu, Maria Letizia Musumeci, Paolo Gisondi, Stefano Piaserico, Paolo Dapavo, Marina Venturini, Gianluca Pagnanelli, Paolo Amerio, Concetta Potenza, Ketty Peris, Franca Cantoresi, Sara Trevisini, Francesco Loconsole, Annamaria Offidani, Santo Raffaele Mercuri, Viviana Lora, Francesca Prignano, Marta Bartezaghi, Giovanni Oliva, Elisabetta Aloisi & Roberto Orsenigo. (2021) Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study. Acta Dermato-Venereologica 101:10, pages adv00576.
Crossref
Crossref
Jamaji C. Nwanaji‐Enwerem, Ugoji Nwanaji‐Enwerem, Andrea A. Baccarelli, Ramone F. Williams & Elena Colicino. (2020) Anti‐tumor necrosis factor drug responses and skin‐blood DNA methylation age: Relationships in moderate‐to‐severe psoriasis. Experimental Dermatology 30:8, pages 1197-1203.
Crossref
Crossref
Yoshinori Umezawa, Akihiko Asahina, Shinichi Imafuku, Yayoi Tada, Shigetoshi Sano, Akimichi Morita, Shinya Sakurai, Naoki Hoshii, Nicola Tilt & Hidemi Nakagawa. (2021) Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results. Dermatology and Therapy 11:3, pages 943-960.
Crossref
Crossref
K.B. Gordon, R.B. Warren, A.B. Gottlieb, A. Blauvelt, D. Thaçi, C. Leonardi, Y. Poulin, M. Boehnlein, F. Brock, C. Ecoffet & K. Reich. (2020) Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2). British Journal of Dermatology 184:4, pages 652-662.
Crossref
Crossref
K. Papp, A. Menter, C. Leonardi, J. Soung, S. Weiss, R. Pillai & A. Jacobson. (2020) Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). British Journal of Dermatology 183:6, pages 1037-1048.
Crossref
Crossref
Elia Álvarez-Coiradas, Cristian R. Munteanu, Laura Díaz-Sáez, Alejandro Pazos, Kilian V.M. Huber, María Isabel Loza & Eduardo Domínguez. (2020) Discovery of novel immunopharmacological ligands targeting the IL-17 inflammatory pathway. International Immunopharmacology 89, pages 107026.
Crossref
Crossref
Arvin Ighani, Jorge R. Georgakopoulos & Jensen Yeung. (2020) Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Giornale Italiano di Dermatologia e Venereologia 155:4.
Crossref
Crossref
L. Puig, I. Alarcón, S. Sulleiro & S. Alfonso. (2020) Opinion Survey on Persistence of Biologic Therapies in Patients with Moderate to Severe Psoriasis. Actas Dermo-Sifiliográficas (English Edition) 111:8, pages 691-694.
Crossref
Crossref
L. Puig, I. Alarcón, S. Sulleiro & S. Alfonso. (2020) Encuesta de opinión a pacientes con psoriasis moderada-grave sobre la persistencia de los tratamientos biológicos. Actas Dermo-Sifiliográficas 111:8, pages 691-694.
Crossref
Crossref
N. Rompoti, P. Sidiropoulou, P. Panagakis, A. Stratigos, M. Papoutsaki, E. Stefanaki, C. Vavouli, M. Politou, A. Befon, P. Kostakis, D. Rigopoulos & E. Nicolaidou. (2020) Real‐world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response. Journal of the European Academy of Dermatology and Venereology 34:6, pages 1240-1247.
Crossref
Crossref
A.B. KimballK.A. Papp, K. Reich, M. Gooderham, Q. LiN. CichanowitzC. La RosaA. Blauvelt. (2019) Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. British Journal of Dermatology 182:6, pages 1359-1368.
Crossref
Crossref
Sebastian Makuch, Marta Woźniak, Monika Krawczyk, Gabriela Pastuch-Gawołek, Wiesław Szeja & Siddarth Agrawal. (2020) Glycoconjugation as a Promising Treatment Strategy for Psoriasis. Journal of Pharmacology and Experimental Therapeutics 373:2, pages 204-212.
Crossref
Crossref
Saori Takamura, Sora Sugai, Ryokichi Taguchi & Yuichi Teraki. (2019) Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue. The Journal of Dermatology 47:3, pages 290-294.
Crossref
Crossref
Luis Puig, Mark Lebwohl, Hervé Bachelez, Jeffrey Sobell & Abby A. Jacobson. (2020) Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial. Journal of the American Academy of Dermatology 82:2, pages 352-359.
Crossref
Crossref
Emma Guttman-Yassky, Ana B. Pavel, Lisa Zhou, Yeriel D. Estrada, Ning Zhang, Hui Xu, Xiangyu Peng, Huei-Chi Wen, Panayiota Govas, Girish Gudi, Vinu CA, Hui Fang, Yacine Salhi, Jonathan Back, Venkateshwar Reddy, Robert Bissonnette, Catherine Maari, Fred Grossman & Gerhard Wolff. (2019) GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology 144:2, pages 482-493.e7.
Crossref
Crossref
P. de la Cueva Dobao, J. Notario, C. Ferrándiz, J.L. López Estebaranz, I. Alarcón, S. Sulleiro, J. Borrás, E. Daudén, J.M. Carrascosa, J.L. Sánchez Carazo, E. Monte Boquet & L. Puig. (2019) Expert consensus on the persistence of biological treatments in moderate‐to‐severe psoriasis. Journal of the European Academy of Dermatology and Venereology 33:7, pages 1214-1223.
Crossref
Crossref
Michael P. Lee, Kevin K. Wu & Jashin J. Wu. 2019. Clinical Cases in Psoriasis. Clinical Cases in Psoriasis
17
22
.
A. Egeberg, M.B. Ottosen, R. Gniadecki, S. Broesby-Olsen, T.N. Dam, L.E. Bryld, M.K. Rasmussen & L. Skov. (2018) Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. British Journal of Dermatology 178:2, pages 509-519.
Crossref
Crossref
Júlia Vide & Sofia Magina. (2017) Moderate to severe psoriasis treatment challenges through the era of biological drugs. Anais Brasileiros de Dermatologia 92:5, pages 668-674.
Crossref
Crossref
D.J. No, M. Amin, S.P. Reddy, A. Egeberg & J.J. Wu. (2017) Sites of recurrence in patients following clearance of psoriasis with biologic therapy. Journal of the European Academy of Dermatology and Venereology 31:6, pages e297-e298.
Crossref
Crossref
MM Hutmacher, K Papp, S Krishnaswami, K Ito, H Tan, R Wolk, H Valdez, C Mebus, ST Rottinghaus & P Gupta. (2017) Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight. CPT: Pharmacometrics & Systems Pharmacology 6:5, pages 322-330.
Crossref
Crossref
Yahiya Y. Syed. (2017) Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis. American Journal of Clinical Dermatology 18:1, pages 147-158.
Crossref
Crossref
Jin-Hyup LeeIn-Kyu ChangHae-Eul LeeMyung ImYoung-Joon SeoJeung-Hoon LeeYoung Lee. (2017) Treatment of Recalcitrant Pyoderma Gangrenosum with Ulcerative Colitis by Adalimumab Injection. Annals of Dermatology 29:2, pages 260.
Crossref
Crossref
Daniel J. No, Mina Amin & Jashin J. Wu. 2017. Clinical Cases in Psoriasis. Clinical Cases in Psoriasis
7
12
.
Daniel J. No, Mina Amin, Stacey Pun & Jashin J. Wu. 2017. Clinical Cases in Psoriasis. Clinical Cases in Psoriasis
95
103
.
A. Egeberg. (2016) Predictors of drug survival for tumour necrosis factor-α and interleukin 12/23 antagonists in psoriasis. British Journal of Dermatology 175:2, pages 247-248.
Crossref
Crossref
Mohn’d AbuHilal, Scott Walsh & Neil Shear. (2016) Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis. Journal of Cutaneous Medicine and Surgery 20:4, pages 313-316.
Crossref
Crossref
A. Menter, K.A. Papp, M. Gooderham, D.M. Pariser, M. Augustin, F.A. Kerdel, S. Fakharzadeh, K. Goyal, S. Calabro, W. Langholff, S. Chavers, D. Naessens, J. Sermon & G.G. Krueger. (2016) Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal of the European Academy of Dermatology and Venereology 30:7, pages 1148-1158.
Crossref
Crossref
Benjamin Farahnik, Kourosh Beroukhim, Tian Hao Zhu, Michael Abrouk, Mio Nakamura, Rasnik Singh, Kristina Lee, Tina Bhutani & John Koo. (2016) Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials. Dermatology and Therapy 6:1, pages 25-37.
Crossref
Crossref
Shivani P. Reddy, Vidhi V. Shah & Jashin J. Wu. 2016. Therapy for Severe Psoriasis. Therapy for Severe Psoriasis
153
162
.
Amit Om, Dane Hill & Steven R. Feldman. 2016. Therapy for Severe Psoriasis. Therapy for Severe Psoriasis
75
82
.
Mark Lebwohl. (2015) Do we need more psoriasis therapies?. The Lancet 386:9993, pages 512-514.
Crossref
Crossref
Hilary S. Bartlett & Ryan P. Million. (2014) Targeting the IL-17–TH17 pathway. Nature Reviews Drug Discovery 14:1, pages 11-12.
Crossref
Crossref
Viraat Patel, Ethan Levin, Eric Sorenson, Mona Malakouti & John Y.M. Koo. (2018) Safety and Efficacy of Combining Biologic with Nonbiologic Therapies for Moderate to Severe Psoriasis: A Review. Psoriasis Forum 20a:4, pages 132-149.
Crossref
Crossref
Junko Takeshita, Shuwei Wang, Daniel B. Shin, Kristina Callis Duffin, Gerald G. Krueger, Robert E. Kalb, Jamie D. Weisman, Brian R. Sperber, Michael B. Stierstorfer, Bruce A. Brod, Stephen M. Schleicher, Andrew D. Robertson, Kristin A. Linn, Russell T. Shinohara, Andrea B. Troxel, Abby S. Van Voorhees & Joel M. Gelfand. (2014) Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting. Journal of the American Academy of Dermatology 71:6, pages 1167-1175.
Crossref
Crossref